Topics

Managing partner at Numerof & Associates.

Articles

A lack of access could shut out patients in need of maintenance drugs for complex conditions.

Pharmacy Deserts are Becoming a National Problem

What does the legislation mean for patient access leaders, pharma brand       managers, and patient service owners? Industry experts weigh in.


The IRA’s Impact on Patient Hub, Access, and Affordability Programs

Videos

In this part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, discusses the impact technology has in relation to patients sticking to their medication plan.

Maintaining a Specialty Medication Regimen 

A founding partner with Curatio Scientia Advisors.

A founding partner with Curatio Scientia Advisor.

Why the integration of AI-enabled solutions has the potential to boost patient support and engagement across numerous patient care settings.


Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment

In an interview with Pharma Commerce Editor Nicholas Saraceno, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, outlines the main challenges surrounding medication adherence. 

Focusing on Psychosocial Factors

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

Who Moved My Prescription? Part V: The Many Layers of Pharmacy Crisis Point

Will the looming changes address the concerns of the patient assistance community?

Looking Ahead to Medicare Reforms Coming in 2025

Gallagher’s 2024 US Physical & Emotional Wellbeing Report outlines ways to meeting evolving needs in the workforce. 

Mental Health, Rising Healthcare Costs Headline Employer and Employee Concerns 

The agreement focuses on augmenting the patient support experience, including from an adherence perspective.

Inizio Engage and Nye Health Strike a Strategic Partnership 

A study explores the cost-effectiveness of combining methotrexate with various drugs as a way to combat failed methotrexate monotherapy.